- Home
- OCFC vs ADPT Comparison
OCFC vs ADPT Comparison
Compare OCFC & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCFC
- ADPT
- Stock Information
- Founded
- OCFC 1902
- ADPT 2009
- Country
- OCFC United States
- ADPT United States
- Employees
- OCFC N/A
- ADPT N/A
- Industry
- OCFC Major Banks
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OCFC Finance
- ADPT Health Care
- Exchange
- OCFC Nasdaq
- ADPT Nasdaq
- Market Cap
- OCFC 1.1B
- ADPT 1.1B
- IPO Year
- OCFC 1996
- ADPT 2019
- Fundamental
- Price
- OCFC $17.01
- ADPT $7.43
- Analyst Decision
- OCFC Hold
- ADPT Strong Buy
- Analyst Count
- OCFC 4
- ADPT 5
- Target Price
- OCFC $21.50
- ADPT $9.40
- AVG Volume (30 Days)
- OCFC 275.7K
- ADPT 2.2M
- Earning Date
- OCFC 04-17-2025
- ADPT 05-06-2025
- Dividend Yield
- OCFC 4.69%
- ADPT N/A
- EPS Growth
- OCFC N/A
- ADPT N/A
- EPS
- OCFC 1.65
- ADPT N/A
- Revenue
- OCFC $375,233,000.00
- ADPT $178,957,000.00
- Revenue This Year
- OCFC N/A
- ADPT $21.21
- Revenue Next Year
- OCFC $13.08
- ADPT $21.98
- P/E Ratio
- OCFC $10.35
- ADPT N/A
- Revenue Growth
- OCFC N/A
- ADPT 5.10
- 52 Week Low
- OCFC $14.03
- ADPT $2.28
- 52 Week High
- OCFC $21.87
- ADPT $9.01
- Technical
- Relative Strength Index (RSI)
- OCFC 43.52
- ADPT 44.19
- Support Level
- OCFC $16.84
- ADPT $6.92
- Resistance Level
- OCFC $17.50
- ADPT $9.01
- Average True Range (ATR)
- OCFC 0.50
- ADPT 0.57
- MACD
- OCFC 0.04
- ADPT -0.01
- Stochastic Oscillator
- OCFC 29.81
- ADPT 24.58
About OCFC OceanFirst Financial Corp.
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management services.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).